Neuland Laboratories Stock Price - ₹22,890.00 | Healthcare

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Neuland Laboratories pivots to high-margin development projects, driving strong profitability and cash generation despite a sharp drop in commercial revenue.

Development revenue grows from ₹14 Cr to ₹418 Cr from Q1 FY26 to Q1 2026-27, highlighting a successful pipeline push.

Commercial revenue falls from ₹488 Cr to ₹20 Cr from Q4 FY26 to Q1 2026-27, signaling a temporary disruption in mature product sales.

EBITDA margin rises from 14% to 35.5% from Q1 FY26 to Q1 2026-27, confirming strong pricing power.

Specialty revenue mix drops from 44% to 8% from Q1 FY26 to Q1 2026-27, indicating a major shift away from this segment.

Working capital days of sale fall from 145 days to 84 days from Q1 FY26 to Q1 2026-27, showing faster cash conversion.

Top 5 products concentration rises from 85% to 89% from Q1 FY26 to Q1 2026-27, keeping product focus narrow.

Top 5 customer concentration drops from 47% to 40% from Q1 FY26 to Q1 2026-27, reducing client dependency.

Prime revenue mix declines from 32% to 18% from Q1 FY26 to Q1 2026-27, showing reduced contribution from this category.

ROCE improves from 5.1% to 35.8% from Q1 FY26 to Q1 2026-27, reflecting much better capital efficiency.

‌
‌
‌

In the news

26 NIFTY500 stocks show 50%+ profit growth in Q1FY27

Neuland Laboratories profit surges 962% to ₹148 crore, shares jump 8%

Neuland Labs hits record ₹19,800 high, launches commercial peptide facility

6 Midcap Stocks Show Strong Q4 Performance Amid Mixed Earnings

HSBC, Jefferies, Goldman Sachs Issue Stock Recommendations for May 15

Neuland Laboratories shares surge 7% on 660% profit jump, Goldman Sachs raises target

Neuland Labs Q4 profit surges 7x to ₹213 crore on export orders